179174-80-2

Basic information

• Product Name: (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol
• Synonyms: (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol
• CAS NO: 179174-80-2
• Molecular Weight: 354.374
• Mol File: 179174-80-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol(179174-80-2)
• EPA Substance Registry System: (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol(179174-80-2)

Safety Data

• Hazardous Substances Data: 179174-80-2(Hazardous Substances Data)

Upstream product

• 162011-83-8 3-(3,4-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one 
• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 

Downstream Products

• 885020-48-4 (2Z)-4-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,4-difluorophenyl)-2-[4-(methylsulfonyl)phenyl]but-2-en-1-ol 
• 179174-81-3 (2Z)-3-(3,4-difluorophenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]but-2-en-1-yl acetate 
• 179174-83-5 (2Z)-4-(acetoxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-enoic acid 
• 179174-82-4 (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenal 

Relevant articles and documents

Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia

A water soluble choline prodrug (17) of a COX-2 selective inhibitor (16) suitable for intravenous dosing in models of cerebral ischemia has been developed. Constant infusion studies using 17 demonstrate that extrapolated brain levels of 16 may be maintained for over 24 h in rats.

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.